14-C-0059, NCT02107963: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors |
|
|
| Completed | 1 | 15 | US | Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide | National Cancer Institute (NCI) | Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma | 08/16 | 01/17 | | |
